secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2025-09-26T23:59:59+00:00
Accession:  0001493152-25-015054
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow signs definitive deal to acquire Melt Pharma for initial $4.3M plus milestones up to ~$352.5M
--------------------------------------------------------------------------------

- Initial cash payment of ~$4.3M for remaining 55% equity; contingent $87.2M upon FDA approval of MELT-300.
- Upon CMS J-Code assignment, Harrow will issue ~1.112M shares of common stock.
- Additional cash payments up to ~$261M based on annual net sales milestones ($100M–$1B).
- Harrow plans NDA submission in 2027, potential US launch in 2028 for MELT-300 sublingual sedation.
- Deal approved by independent committee; fairness opinion from Lake Street Capital Markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225015054/0001493152-25-015054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225015054/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-015054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer